Nyrada Inc. CEO James Bonnar talked with Proactive about the company’s progress developing a first-in-class TRPC ion channel blocker. This drug candidate is currently in a Phase I clinical trial and has demonstrated both neuroprotective and cardioprotective effects in preclinical models. Bonnar explained that TRPC channels play a crucial role in cellular injury, especially in heart and brain cells, and once these cells die, they are difficult to regenerate. Bonnar said the drug is showing efficacy in three key indications: stroke, traumatic brain injury, and myocardial infarction. “This drug is shown broad activity in these three indications, and it's really proving itself to be a Swiss Army knife type drug,” he noted. Recent preclinical results highlighted strong cardioprotective effects, including an 86% preservation of myocardial tissue and anti-arrhythmic activity — a key benefit given the risk of sudden cardiac death in heart attack patients. The Phase I study involves dose escalation in healthy volunteers, and so far, safety benchmarks have been met in the first two cohorts. Nyrada plans to complete the study by Q3, paving the way for Phase II trials in patient populations. For more updates on Nyrada and other biotech innovators, visit Proactive’s YouTube channel. Don’t forget to like this video, subscribe to the channel, and turn on notifications so you never miss an update. #Nyrada #BiotechStocks #TRPCBlocker #Cardioprotection #Neuroprotection #StrokeTreatment #HeartAttackRecovery #PharmaInnovation #DrugDevelopment #ClinicalTrials #ProactiveInvestors